Can afamelanotide replace sunscreen for EPP patients?

No. Afamelanotide enhances melanin production, reducing phototoxic risk, but it's not a complete sun replacement. EPP patients must still use broad-spectrum sunscreen, protective clothing, and UV-blocking sunglasses. Afamelanotide is an adjunctive tool that expands safe outdoor time when combined with rigorous sun protection.

Is colistin used for routine bacterial infections?

No. Colistin is reserved for serious infections caused by multidrug-resistant gram-negative bacteria when first-line antibiotics have failed. Its nephrotoxicity and neurotoxicity risk mean it's only justified when the infection is life-threatening and alternatives are exhausted.

Why is colistin approved in Canada but afamelanotide is not?

Health Canada's regulatory pathways differ from the FDA and EMA. Colistin's longer history, broader antimicrobial use, and established hospital protocols gave it approval. Afamelanotide, being indicated for a rare disease, may not have met Health Canada's specific review timeline or requirements at the time of FDA/EMA approval.

Which compound has more clinical trial data?

Colistin has significantly more: 119 clinical trials recorded versus 23 for afamelanotide. This reflects colistin's decades of use in hospital settings and the extensive research into resistance patterns and dosing protocols.

Can either compound be used off-label for other conditions?

Both are approved compounds with specific licensed indications. Off-label use is a matter between a patient and their prescribing physician. Afamelanotide is approved only for EPP; colistin only for resistant gram-negative infections. Any other use would fall outside the approved indication.

Afamelanotide vs Colistin: Key Differences & Uses

Afamelanotide and colistin are both FDA-approved compounds, but they work in completely different ways for different conditions. Afamelanotide is a melanocyte-stimulating hormone (MSH) analogue designed to stimulate melanin production in the skin, primarily used to prevent phototoxic reactions in patients with erythropoietic protoporphyria (EPP). Colistin, by contrast, is an antibiotic peptide that works by disrupting bacterial cell membranes and is reserved for serious infections caused by multidrug-resistant gram-negative bacteria when other antibiotics have failed. Their mechanisms, indications, and clinical contexts are entirely distinct—this comparison helps you understand which compound addresses which health scenario.

What is Afamelanotide?

Afamelanotide is a synthetic peptide analogue of alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring signalling molecule in the body. The compound was approved by the FDA in 2014 under the brand name Scenesse, and by the EMA in 2014 as well.

The drug works by binding to melanocortin receptors on melanocytes (the pigment-producing cells in skin), triggering an increase in melanin synthesis. This enhanced melanin production provides a protective effect against harmful UV radiation exposure.

Clinical Use of Afamelanotide

Afamelanotide is indicated specifically for erythropoietic protoporphyria (EPP), a rare genetic disorder where patients experience severe, debilitating phototoxic reactions upon sun exposure. EPP patients lack sufficient enzyme activity in the heme synthesis pathway, causing accumulation of protoporphyrins that react with light to produce intense pain, swelling, and tissue damage in sun-exposed skin.

The clinical evidence is robust: a phase 3 randomised controlled trial showed that afamelanotide combined with sun protection significantly reduced the duration and severity of phototoxic episodes compared to placebo. Among the 23 clinical trials recorded for afamelanotide, this approval class demonstrates strong efficacy data.

What is Colistin?

Colistin is an older antimicrobial peptide antibiotic, discovered in 1947 and derived from the bacterium Bacillus polymyxa. It's approved by the FDA, EMA, and Health Canada—making it more globally approved than afamelanotide.

Colistin works by binding to the lipopolysaccharide (LPS) layer and phospholipids in gram-negative bacterial cell membranes, causing membrane disruption and bacterial cell death. It's a bactericidal agent, meaning it actively kills bacteria rather than simply inhibiting their growth.

Clinical Use of Colistin

Colistin is an antibiotic reserved for serious infections caused by multidrug-resistant gram-negative bacteria, particularly Pseudomonas aeruginosa and Acinetobacter baumannii, when first-line antibiotics have failed or are ineffective. With 119 clinical trials recorded, colistin has an extensive research and clinical use history.

It's typically administered intravenously or inhaled for respiratory infections. The compound remains crucial in managing hospital-acquired infections and ventilator-associated pneumonia caused by resistant pathogens.

Key Differences at a Glance

| Aspect | Afamelanotide | Colistin | |---|---|---| | Drug Class | Melanocortin agonist | Antibiotic peptide | | Mechanism | Stimulates melanin production | Disrupts bacterial cell membrane | | Primary Use | Erythropoietic protoporphyria (EPP) | Multidrug-resistant gram-negative infections | | Route of Administration | Subcutaneous implant (2x yearly) | IV or inhaled | | FDA Status | Approved (2014) | Approved | | EMA Status | Authorised (2014) | Authorised | | Health Canada Status | Not approved | Approved | | Clinical Trials | 23 recorded | 119 recorded | | Therapeutic Goal | Prevention (photoprotection) | Treatment (bacterial infection) |

Regulatory Status & Global Availability

Afamelanotide: FDA and EMA approved; not approved in Canada. Approved compounds are available through licensed healthcare providers in the US and EU, typically for identified EPP patients following a diagnostic pathway.

Colistin: FDA, EMA, and Health Canada approved. Broader global regulatory acceptance reflects its longer history and wider clinical application across hospital systems worldwide.

Both compounds have strong Evidence Grade A ratings, indicating high-quality clinical trial data supporting their safety and efficacy profiles.

Clinical Evidence Comparison

Afamelanotide Evidence Base

The pivotal phase 3 trial enrolled EPP patients and measured phototoxic episodes as the primary endpoint. Results showed afamelanotide significantly reduced episode duration and severity. The mechanism—melanin photoprotection—is well-established and consistent with the pathophysiology of EPP.

Adverse events were generally mild, including injection-site reactions and some patients reporting facial flushing.

Colistin Evidence Base

With 119 clinical trials, colistin's evidence base spans decades of antimicrobial resistance research. Numerous studies confirm its bactericidal activity against resistant gram-negative organisms. However, colistin carries a risk profile that includes nephrotoxicity (kidney damage) and neurotoxicity, particularly at higher doses or in prolonged therapy.

The clinical trade-off: colistin is often a last-resort option for life-threatening infections when alternatives are unavailable.

Who Is Each Compound Best Suited For?

Afamelanotide is Best For:

EPP patients seeking to expand their safe outdoor time and quality of life
Individuals who have been formally diagnosed with erythropoietic protoporphyria by a specialist
Patients motivated to use sun protection consistently (afamelanotide is preventive, not a complete substitute for sunscreen and protective clothing)
Those willing to comply with subcutaneous implant placement twice yearly

Colistin is Best For:

Patients with documented multidrug-resistant gram-negative bacterial infections
Hospital settings managing ventilator-associated pneumonia or nosocomial infections
Cases where carbapenem-resistant Pseudomonas or Acinetobacter infection is confirmed
Situations where other antibiotics (fluoroquinolones, beta-lactams) have failed or are contraindicated

Related Compounds & Resources

If you're exploring peptide therapeutics more broadly, you might also investigate α-MSH analogues like melanotan II for research contexts, or other antibiotic peptides used in resistant infection management. For rare genetic conditions, familial Mediterranean fever peptide research represents another frontier in peptide medicine.

Learn more about peptide bioavailability and peptide mechanisms in our glossary.

Safety & Tolerability

Afamelanotide: Generally well-tolerated. Common side effects include injection-site reactions (erythema, induration). Some patients report darkening of existing moles and increased mole formation, which requires dermatologic monitoring.

Colistin: Nephrotoxicity and neurotoxicity are the primary concerns, dose-dependent and reversible in most cases. Monitoring of renal function and neurological status is essential during therapy. These risks are accepted because the alternative—untreated multidrug-resistant infection—is often fatal.

Bottom Line

Afamelanotide and colistin are entirely different therapeutic tools: one is a photoprotective agent for a rare genetic disease, the other is an antibiotic of last resort for resistant infections. There's no meaningful "versus" between them—they treat different medical conditions with different mechanisms. The choice of which one matters depends entirely on your clinical situation: Are you managing EPP (afamelanotide) or treating a resistant bacterial infection (colistin)?

Afamelanotide vs Colistin: How These Approved Compounds Differ